Episode Details

Back to Episodes
A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In

A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In

Published 1 month ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-procedure-uses-donor-tissue-to-keep-the-eye-s-drainage-canal-open-first-human-results-are-in

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In Short answer: The first results are encouraging, but they do not yet show that donor tissue makes canaloplasty more durable. The reported 52-eye study has no published full paper, no control group, and only six months of follow-up. Because the procedure was combined with cataract surgery, some—and possibly a substantial part—of the pressure drop may have come from cataract removal rather than the allograft. The idea is plausible: open Schlemm’s canal, then support it with donor tissue. But the key claim—that this support prevents clinically important canal recoil and improves lasting pressure control—still needs a randomized comparison. Evidence reviewed through October 16, 2026. What the first 52-eye results show On October 8, 2026, Iantrek announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canaloplasty combined with cataract surgery. The company reported outcomes for 52 treated eyes. The full study report was not published with the announcement; the data were described as “on file” and subject to further analysis. (Iantrek’s October 8 announcement, Ophthalmology Management’s report) For the full table, please open this article on visualfieldtest.com. The 14.1 figure is calculated, not separately published: 22.4 × (1 − 0.372) = 14.07. Because the baseline and percentage are rounded, the exact study mean might differ slightly. The medication calculation is also approximate: a 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61. These are the figures in the company announcement, not independently audited results. “No serious adverse events” does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems. Important study details are not yet public The announcement does not provide enough information to establish several facts requested for a proper clinical assessment: Glaucoma severity and subtype: Not reported for the 52-eye cohort. Patient age: Not reported. Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery: Not reported. Detailed inclusion criteria: Not reported. Medication washout before baseline pressure measurement: Not reported. This matters: a pressure measured after stopping drops is not directly comparable with one measured while patients are taking them. Cataract surgery: The study is described as bio-reinforced canaloplasty performed with cataract surgery. That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table. Exact surgical steps: The type of dilation, how much of the canal was treated, and the precise graft-placement steps are not reported. Allograft length and exact placement extent: Not reported for AlloSpan. Postoperative eye-drop regimen: Not reported. A separate, ongoing study called BOOST is registered as an observational study of bio-reinforced canaloplasty. Its registry describes placing minimally manipulated, homologous-use scleral allograft tissue in the wall region of Schlemm’s canal after canaloplasty. It targets

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us